Advertisement
Advertisement
U.S. markets open in 4 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.19+1.20 (+2.67%)
At close: 04:00PM EDT
46.19 0.00 (0.00%)
After hours: 04:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close44.99
Open45.41
Bid0.00 x 1100
Ask0.00 x 4000
Day's Range45.41 - 46.52
52 Week Range25.04 - 48.82
Volume1,108,115
Avg. Volume983,957
Market Cap6.446B
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IONS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ionis Pharmaceuticals, Inc.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
  • InvestorPlace

    3 Biotech Stocks to Sell in October

    This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market. Hence, investors are scrambling to streamline their portfolios. In doing so, they might want to think about some biotech stocks to sell. Biotech stocks have typically been among the most risky investments. These firms spend a ton of money on research and development an

  • GlobeNewswire

    Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

    Enhancing the depth of 5AM’s scientific and operational expertiseSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, whi

  • Investor's Business Daily

    Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

    Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Advertisement
Advertisement